YIELD10 BIOSCIENCE, INC.: Nasdaq/NYSE listing notice — Yield10 Bioscience gets Nasdaq deficiency letter for equity of $1.143M, below $2.5M minimum

YIELD10 BIOSCIENCE, INC.

Received Nasdaq deficiency letter on May 18, 2023 for failing minimum stockholders' equity requirement.
Stockholders' equity reported at $1,143,000 as of March 31, 2023, well below the $2.5M threshold.
Must submit a compliance plan by July 3, 2023; Nasdaq may grant up to 180-day extension if plan accepted.
No immediate effect on listing; company can appeal a rejected plan to Nasdaq Hearings Panel.
Company intends to submit plan and explore options but cannot assure regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 18, 2023, Yield10 Bioscience, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the quarter ended Mar

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001121702-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.